Since the implementation of the EU Orphan Regulation in 2000, the Committee for Orphan Medicinal Products at the European Medicines Agency has been evaluating the benefits of proposed orphan medicines vs. satisfactory treatment methods. This type of evaluation is foreseen in the Orphan Regulation as the orphan designation criterion called the "significant benefit." In this article, based on 20 years of experience, we provide a commentary explaining what is considered a satisfactory method of treatment in the context of the EU Orphan Regulation and for the purpose of the assessment of significant benefit. We discuss the challenges posed by continuously changing clinical practise, which is associated with the increasing number of treatment options, evolving nature of medicinal therapeutic indications and our understanding of them.
Keywords: committee for orphan medicinal products; orphan designation; orphan regulation; satisfactory methods of treatment; significant benefit.
Copyright © 2021 Sheean, Naumann-Winter, Capovilla, Kalland, Malikova, Mariz, Matusevicius, Nistico, Schwarzer-Daum, Tsigkos, Tzogani, Larsson, Magrelli and Stoyanova-Beninska.